Zoledronic Acid in First-Line Treatment of Prostate Cancer

被引：3
作者：
Pinkawa, Michael
机构：
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 97卷 / 01期
关键词：
ANDROGEN-DEPRIVATION THERAPY; TROG; 03.04; RADAR; PHASE-3; TRIAL; SHORT-TERM; RADIOTHERAPY; SUPPRESSION; MEN;
D O I：
10.1016/j.ijrobp.2016.06.2453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 8
页数：3
相关论文
共 14 条
[1]   Oncology Scan-New Treatment and No Treatment: Enduring Issues in the Management of Prostate Cancer [J].
Buyyounouski, Mark K. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (01) :1-2
[2]   Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial [J].
Denham, James W. ;
Steigler, Allison ;
Joseph, David ;
Lamb, David S. ;
Spry, Nigel A. ;
Duchesne, Gillian ;
Atkinson, Chris ;
Matthews, John ;
Turner, Sandra ;
Kenny, Lizbeth ;
Tai, Keen-Hun ;
Gogna, Nirdosh Kumar ;
Gill, Suki ;
Tan, Hendrick ;
Kearvell, Rachel ;
Murray, Judy ;
Ebert, Martin ;
Haworth, Annette ;
Kennedy, Angel ;
Delahunt, Brett ;
Oldmeadow, Christopher ;
Holliday, Elizabeth G. ;
Attia, John .
RADIOTHERAPY AND ONCOLOGY, 2015, 115 (03) :301-307
[3]   Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial [J].
Denham, James W. ;
Joseph, David ;
Lamb, David S. ;
Spry, Nigel A. ;
Duchesne, Gillian ;
Matthews, John ;
Atkinson, Chris ;
Tai, Keen-Hun ;
Christie, David ;
Kenny, Lizbeth ;
Turner, Sandra ;
Gogna, Nirdosh Kumar ;
Diamond, Terry ;
Delahunt, Brett ;
Oldmeadow, Christopher ;
Attia, John ;
Steigler, Allison .
LANCET ONCOLOGY, 2014, 15 (10) :1076-1089
[4]   Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer [J].
Denham, James W. ;
Nowitz, Michael ;
Joseph, David ;
Duchesne, Gillian ;
Spry, Nigel A. ;
Lamb, David S. ;
Matthews, John ;
Turner, Sandra ;
Atkinson, Chris ;
Tai, Keen-Hun ;
Gogna, Nirdosh Kumar ;
Kenny, Lizbeth ;
Diamond, Terry ;
Smart, Richard ;
Rowan, David ;
Moscato, Pablo ;
Vimieiro, Renato ;
Woodfield, Richard ;
Lynch, Kevin ;
Delahunt, Brett ;
Murray, Judy ;
D'Este, Cate ;
McElduff, Patrick ;
Steigler, Allison ;
Kautto, Allison ;
Ball, Jean .
BJU INTERNATIONAL, 2014, 114 (03) :344-353
[5]   Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].
James, Nicholas D. ;
Sydes, Matthew R. ;
Clarke, Noel W. ;
Mason, Malcolm D. ;
Dearnaley, David P. ;
Spears, Melissa R. ;
Ritchie, Alastair W. S. ;
Parker, Christopher C. ;
Russell, J. Martin ;
Attard, Gerhardt ;
de Bono, Johann ;
Cross, William ;
Jones, Rob J. ;
Thalmann, George ;
Amos, Claire ;
Matheson, David ;
Millman, Robin ;
Alzouebi, Mymoona ;
Beesley, Sharon ;
Birtle, Alison J. ;
Brock, Susannah ;
Cathomas, Richard ;
Chakraborti, Prabir ;
Chowdhury, Simon ;
Cook, Audrey ;
Elliott, Tony ;
Gale, Joanna ;
Gibbs, Stephanie ;
Graham, John D. ;
Hetherington, John ;
Hughes, Robert ;
Laing, Robert ;
McKinna, Fiona ;
McLaren, Duncan B. ;
O'Sullivan, Joe M. ;
Parikh, Omi ;
Peedell, Clive ;
Protheroe, Andrew ;
Robinson, Angus J. ;
Srihari, Narayanan ;
Srinivasan, Rajaguru ;
Staffurth, John ;
Sundar, Santhanam ;
Tolan, Shaun ;
Tsang, David ;
Wagstaff, John ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10024) :1163-1177
[6]   Addition of Radiotherapy to Long-Term Androgen Deprivation in Locally Advanced Prostate Cancer: An Open Randomised Phase 3 Trial [J].
Mottet, Nicolas ;
Peneau, Michel ;
Mazeron, Jean-Jacques ;
Molinie, Vincent ;
Richaud, Pierre .
EUROPEAN UROLOGY, 2012, 62 (02) :213-219
[7]   The anti-tumour activity of bisphosphonates [J].
Neville-Webbe, HL ;
Holen, I ;
Coleman, RE .
CANCER TREATMENT REVIEWS, 2002, 28 (06) :305-319
[8]   Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J].
Saad, F ;
Gleason, DM ;
Murray, R ;
Tchekmedyian, S ;
Venner, P ;
Lacombe, L ;
Chin, JL ;
Vinholes, JJ ;
Goas, JA ;
Zheng, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :879-882
[9]   Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer [J].
Smith, Matthew R. ;
Egerdie, Blair ;
Toriz, Narciso Hernandez ;
Feldman, Robert ;
Tammela, Teuvo L. J. ;
Saad, Fred ;
Heracek, Jiri ;
Szwedowski, Maciej ;
Ke, Chunlei ;
Kupic, Amy ;
Leder, Benjamin Z. ;
Goessl, Carsten .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :745-755
[10]   Oncology Scan-Rising Stars, Fading Stars, and Shooting Stars: New Trends in Prostate Cancer Management [J].
Song, Danny Y. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (01) :4-6
12